Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of EBITDA Margin data on record, last reported at 65.61% in Q2 2024.

  • On a quarterly basis, EBITDA Margin rose 316698.0% to 65.61% in Q2 2024 year-over-year; TTM through Jun 2025 was 94.12%, a 5724.0% decrease, with the full-year FY2024 number at 11.82%, up 343466.0% from a year prior.
  • EBITDA Margin reached 65.61% in Q2 2024 per FULC's latest filing, up from 3213.78% in the prior quarter.
  • Over the last five years, EBITDA Margin for FULC hit a ceiling of 65.61% in Q2 2024 and a floor of 9471.19% in Q1 2023.
  • A 5-year average of 2041.4% and a median of 1028.79% in 2020 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -844414bps in 2023, then surged 316698bps in 2024.
  • Tracing FULC's EBITDA Margin over 5 years: stood at 420.19% in 2020, then decreased by -12bps to 470.42% in 2021, then plummeted by -768bps to 4083.65% in 2022, then increased by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
  • Business Quant data shows EBITDA Margin for FULC at 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.